The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022.
Expert Opin Investig Drugs
; 31(11): 1203-1226, 2022 Nov.
Article
in En
| MEDLINE
| ID: mdl-36413823
ABSTRACT
INTRODUCTION:
Triple-negative breast cancer (TNBC) accounts for 15-20% of breast cancers (BC) and has the worst prognosis. It is characterized by the absence of both hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2). TNBC has more limited therapeutic options compared to other subtypes, meaning that there is still a long way to go to discover target treatments. AREAS COVERED Our review aims to summarize phase II/III clinical trials enrolling patients with TNBC that have been published between 2017 and 2022 but failed to reach their primary endpoint. We here try to emphasize the limitations and weaknesses noted in negative studies and to point out unexpected results which might be useful to enhance the therapeutic approach to TNBC disease. EXPERT OPINION A deeper understanding of the mechanisms behind TNBC heterogeneity allowed to enhance the knowledge of new prognostic and predictive biomarkers of response. However, it is also through several failed clinical trials that we were able to define new therapeutic approaches which improved TNBC patients' clinical outcomes. Nowadays, we still need to overcome several difficulties to fully recognize different intracellular and extracellular pathways that crosstalk in TNBC and the mechanisms of resistance to identify novel tailored-patients' therapies.Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Triple Negative Breast Neoplasms
Type of study:
Prognostic_studies
Limits:
Humans
Language:
En
Journal:
Expert Opin Investig Drugs
Journal subject:
TERAPIA POR MEDICAMENTOS
Year:
2022
Document type:
Article
Affiliation country:
Italia